IBTK and myeloid sarcoma: Advantages of BTKi as a treatment option for MS over traditional B-cell depleting monoclonal antibodies include less potential risk of chronic immunosuppression and dual effects via peripheral modulation of B- and other innate immune cell signaling pathways and central inhibition of CNS-resident, innate microglia and astrocytes.